The Severe Asthma Registry – The German Patients

German Asthma Net e.V.

S. Korn[1], M. Wilk[1], C. Schulz[2], R. Ehmann[3], M. Idzko[4], E. Hamelmann[5], R. Buhl[1]
and all participating centers of the German Severe Asthma Registry

[1] Pulmonary Department, Mainz University Hospital, [2] Dept. Internal Medicine II, Regensburg University Hospital,
[3] Ambulante Pneumologie Dres. Heimann/Ehmann Stuttgart, Germany, [4] University of Freiburg, [5] Evangelisches Krankenhaus Bielefeld, Germany

Introduction and aim

- Patients with severe persistent asthma represent the highest unmet medical need among the asthmatic population
- Severe Asthma Registry in Germany since 2011

- Aim: To characterize patients with severe asthma in Germany and to improve the understanding of underlying mechanisms and disease progression

Patients

- 1308 patients (September 2018) with severe asthma in Germany, Austria and Slovenia
- 869 German patients

- detailed clinical and functional evaluations, including patients' medical history, allergy and lung function tests, blood analyses as well as past and concomitant medication and comorbidities

- Patient characteristics at inclusion

Inclusion criteria for adults

High level of treatment (A), i.e. step 5 of GINA guideline
or (B) medium level of treatment and poor symptom control:

(A) High level of treatment:

a. Maintenance treatment with high-dose inhaled corticosteroids (≥ 1000 µg beclomethasone (BDP, powder) or equivalent) in combination with LABA or LTRA or theophylline

or

b. Maintenance treatment with oral corticosteroids (OCS) for ≥3 months independent of other asthma treatments

or

c. Treatment with omalizumab or mepolizumab independent of other asthma treatments

B) Medium level of treatment and poor symptom control:

a. Maintenance treatment with medium to high doses of ICS (≥ 500 µg BDP (powder) or equivalent) in combination with LABA or LTRA or theophylline

and

b. **Poor symptom control:**

(i) asthma symptoms ≥ 3 x / week or use of rescue medication ≥ 3 x / week;

or

(ii) activities limited due to asthma;

or

(iii) any nighttime asthma symptoms;

or

(iv) ≥ 1 exacerbation in the last year with ≥ 3 days of OCS treatment

or

(v) FEV1<80% of predicted

Adult German patients

Age (mean ± SEM)	50.6 ± 0.5 yrs.
Sex	60.1% female
FEV1 (L, % pred.)	1.97 ± 0.03 L 64 ± 0.8%
Exhaled NO (median, IQ range)	36 (18-65) ppb
Partly or uncontrolled asthma (GINA)	88%
Exacerbations (last 12 months)	4.0 ± 0.2
Allergic asthma	46.7%
Oral glucocorticosteroids	43.7%
Omalizumab	30.6%
Anti-IL-5 antibodies	8.3%
Follow-up	1 year: 348 pts 2 years: 199 pts

Documentation of antibody therapy

Conclusion

- Patient recruitment ongoing → further characterization of clinical, functional, cellular and biochemical parameters related to severe asthma
- Longitudinal assessment by yearly follow-up evaluation
- The Severe Asthma Registry may help to confirm and extend results obtained in similar databases